Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when BCTX files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsBriaCell raises $4.71M through sale of 1.45M shares at $3.25, diluting existing holders
Filed June 3, 2026 · Period ending May 31, 2026 · ~1 min read
Key Changes
-
high
Company sold 1.45 million shares at $3.25 each, raising $4.71M gross proceeds before fees. Funds will support working capital and business objectives. Offering closed June 2, 2026.
Item 1.01 verify on EDGAR → -
medium
Placement agent ThinkEquity received 7.5% cash fee (~$353K) plus warrants to buy 72,465 shares at $4.0625 (25% premium to offering price), exercisable immediately for five years.
Item 1.01 verify on EDGAR → -
medium
Shares sold under existing shelf registration from January 2024. Placement agent warrants issued as private placement, not registered, representing additional 5% dilution versus shares sold.
Item 3.02 verify on EDGAR →
Summary
BriaCell completed a $4.71 million capital raise by selling 1.45 million common shares at $3.25 per share through placement agent ThinkEquity. The offering closed June 2, 2026, with proceeds earmarked for working capital and advancing the company's business objectives. This represents immediate dilution to existing shareholders, increasing the share count by approximately 1.45 million.
The placement agent received standard compensation: a 7.5% cash fee and warrants to purchase 72,465 shares at $4.0625, exercisable for five years. These warrants add potential future dilution of roughly 5% beyond the shares already sold. The $4.0625 exercise price sits 25% above the offering price, suggesting the agent expects meaningful upside.
Retail holders should monitor how quickly BriaCell deploys this capital and whether it extends the company's cash runway sufficiently to reach key clinical milestones. Watch for updates on trial progress or partnership announcements that could justify the dilution and validate the higher warrant strike price.
Section-by-Section Diff
Event · Item 1.01 — Entry into a Material Definitive Agreement
Item 1.01 — Entry into a Material Definitive Agreement filed; see Key Changes for terms.
Added in current filing · verify on EDGAR →
As part of its compensation for acting as Placement Agent for the Offering, the Company paid the Placement Agent a cash fee of 7.5% of the aggregate gross proceeds and also issued to the Placement Agent warrants to purchase 72,465 common shares (the “Placement Agent Warrants”). The Placement Agent Warrants are exercisable upon issuance, expire five years from the date of the Agreement, and have an exercise price of $4.0625 per common share.
ThinkEquity received a 7.5% cash fee on gross proceeds (approximately $353,000) plus warrants to purchase 72,465 shares. These warrants are immediately exercisable, expire in five years, and have an exercise price of $4.0625 per share, representing a 25% premium to the offering price. The warrants represent potential additional dilution of approximately 5% of the shares sold in the offering.
Show 1 minor / wording change
Added in current filing · verify on EDGAR →
The 1,449,300 common shares sold in the Offering were offered and sold pursuant to a registration statement on Form S-3 (File No. 333-276650), which was filed with the Securities and Exchange Commission (the “Commission”) on January 22, 2024, and was declared effective by the Commission on January 31, 2024.
The common shares were sold under an existing shelf registration statement filed in January 2024. The placement agent warrants and underlying shares were issued under a private placement exemption (Section 4(a)(2)) rather than the registration statement. This is standard structure for placement agent compensation in registered offerings.
Event · Item 3.02 — Unregistered Sales of Equity Securities
BriaCell disclosed unregistered sales of equity securities, specifically Placement Agent Warrants and underlying shares.
Added in current filing · verify on EDGAR →
The disclosure set forth in Item 1.01 of this Current Report on Form 8-K regarding the Placement Agent Warrants and the shares issuable thereunder are hereby incorporated by reference.
The company disclosed unregistered sales of equity securities under Item 3.02, specifically referencing Placement Agent Warrants and shares issuable upon exercise of those warrants. The full details are incorporated by reference from Item 1.01 of the same 8-K filing, which is not included in the provided text.
Event · Item 8.01 — Other Events
BriaCell announced pricing on May 31 and closing on June 2 of an offering via press releases.
Added in current filing · verify on EDGAR →
On May 31, 2026, the Company issued a press release announcing the pricing of the Offering.
The company disclosed that it priced an offering on May 31, 2026. The 8-K does not provide details on the offering size, price, or securities type; those details are in the referenced press release exhibit.
Added in current filing · verify on EDGAR →
On June 2, 2026, the Company issued a press release announcing the closing of the Offering.
The company disclosed that the offering closed on June 2, 2026. This indicates the capital raise transaction was completed. Specific terms and proceeds would be in the attached press release.
Event · Item 9.01 — Financial Statements and Exhibits
BriaCell disclosed a securities offering via placement agent, with pricing announced May 31 and closing June 2, 2026.
Added in current filing · verify on EDGAR →
Exhibit No. | Description | 4.1 | Form of Placement Agent Warrant | 5.1 | Opinion of Bennett Jones LLP | 10.1 | Placement Agency Agreement | 23.1 | Consent of Bennett Jones LLP (included in Exhibit 5.1) | 99.1 | Pricing Press Release dated May 31, 2026 | 99.2 | Closing Press Release dated June 2, 2026
BriaCell completed a securities offering through a placement agent. The 8-K attaches the placement agency agreement, placement agent warrants, legal opinion, and two press releases covering pricing (May 31) and closing (June 2). This indicates the company raised capital through a private placement or registered direct offering, issuing warrants to the placement agent as compensation. The specific terms, amount raised, and securities issued would be detailed in the attached exhibits and press releases.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Jun 10, 2026 · How we verify